Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) Enterprise Value (2020 - 2025)

RxSight's Enterprise Value history spans 6 years, with the latest figure at -$228.1 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 50.16% year-over-year to -$228.1 million; the TTM value through Dec 2025 reached -$228.1 million, up 50.16%, while the annual FY2025 figure was -$228.1 million, 50.16% up from the prior year.
  • Enterprise Value reached -$228.1 million in Q4 2025 per RXST's latest filing, up from -$425.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$80.7 million in Q2 2021 to a low of -$457.7 million in Q4 2024.
  • Average Enterprise Value over 5 years is -$247.8 million, with a median of -$233.3 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: tumbled 2567.87% in 2021, then soared 63.68% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$291.3 million in 2021, then skyrocketed by 63.68% to -$105.8 million in 2022, then crashed by 131.27% to -$244.7 million in 2023, then crashed by 87.06% to -$457.7 million in 2024, then surged by 50.16% to -$228.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Enterprise Value are -$228.1 million (Q4 2025), -$425.4 million (Q3 2025), and -$410.6 million (Q2 2025).